Topic: Vimpat
Data on Keppra XR (levetiracetam) extended release tablets and Brivaracetam will also be presented. Keppra XR was approved in September 2008 as an add-on therapy for POS in patients who are 16 years of age and older with epilepsy. Following is a ...
ATLANTA, June 29, 2010 /PRNewswire/ ? New long term data showed that Vimpat? (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. Vimpat ...
Guide to Lacosamide Posters for Science Writers Attending the 62nd Annual Meeting of the American Academy of Neurology (AAN) -. "The breadth and depth of Vimpat data being presented at AAN suggests that the neurology community recognizes the important role of Vimpat ...
New long-term safety and efficacy data build confidence in AED Vimpat; data presented at AES meeting
Long-term data presented at American Epilepsy Society annual meeting demonstrate sustained efficacy and consistent tolerability profile ? Rates of cognitive adverse events similar to those associated with placebo ? Novel mechanism of action differs from traditional sodium channel agents ? Experts comment ...
Vimpat(R) demonstrated greater seizure reduction and improved seizure freedom versus placebo when added to first and second-generation antiepileptic drugs (AEDs). - Phase III study supports recent U.S. FDA and European Commission approvals of Vimpat(R). Vimpat(R) was recently approved by the U.S. Food ...
Vimpat(R) Provides Early Efficacy and Efficacy across Doses as Adjunctive Therapy; Vimpat(R) Demonstrates Consistent Seizure Reduction When Added to Concomitant Treatments; Vimpat(R) Is Generally Well-Tolerated. The analyses also showed that Vimpat(R) provides consistent seizure reduction versus placebo, when added to concomitant AEDs, ...
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Vimpat (lacosamide), a new antiepileptic drug (AED). "At UCB, we are thrilled that Vimpat will be a new option for people with epilepsy in the U.S. living with uncontrolled ...
